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Background Spinal cord injury (SCI) leads to serious complications involving primary 
trauma and progressive loss due to inflammation, local ischemia, or infection. Despite 
a worldwide annual incidence of 15 to 40 cases per million, methylprednisolone is 
the only treatment available to alleviate neurologic dysfunction; therefore, research is 
currently focused on identifying novel targets by biochemical and molecular studies.
Purpose Here, we investigated the expression of various molecular markers at the 
messenger ribonucleic acid (mRNA) and protein level at day 0 and day 30 post-SCI.
Methods Enzyme-linked immunosorbent assay (ELISA) was performed to determine 
the expression of CASPASE-3 and heat shock protein-27 (HSP-27) in serum samples. 
Real-time polymerase chain reaction (RT-PCR) was performed to determine the level 
of mRNA expression of vascular endothelial growth factor receptor-1 (VEGFR-1), VEG-
FR-2, HSP-27, monocyte chemoattractant protein-1 (MCP-1), and CASPASE-3.
Results HSP-27 expression at day 30, as compared with day 0, showed significant 
downregulation. In contrast, there was elevated expression of MCP-1. ELISA analysis 
showed no significant change in the expression of CASPASE-3 or HSP-27.
Conclusion There may be possible opposing role of HSP-27 and MCP-1 governing 
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Introduction
Injury to the spinal cord less than 3 weeks of age is consid-
ered acute spinal cord injury (SCI). SCI results in devastat-
ing complications, and the reversal of resulting deficits is a 
challenge for medical research. Despite extensive research 
to understand the pathophysiology of SCI, there exists no 
effective treatment that can reverse the deficits or interrupt 
the ongoing damage to the spinal cord following SCI.1 Most 
SCIs are reported from high-velocity road traffic accidents, 
falls, crimes, and recreational activities with the incidence of 
injuries on the rise in geriatric populations.2 Cervical spine is 
commonly affected as it is the most flexible region.3
A biphasic phenomenon best describes the pathophysi-
ology of SCI. This includes a primary phase and secondary 
phase of injury.4 The primary injury is caused by initial trau-
ma, ischemia, demyelination, or infection. Further damage to 
the spinal cord continues in the secondary phase of injury 
characterized by tissue edema, electrolyte imbalance, cell 
death, free radical formation, excitotoxicity, chemotaxis, and 
immune cells infiltration.5 Once initiated, all these mecha-
nisms perpetuate a self-propagating cycle leading to delete-
rious consequences.
To stabilize the spinal column and prevent further dam-
age, urgent intervention is required soon after surgery. Cur-
rent treatments use a combination of medical, surgical, and 
rehabilitation therapy6 although advantages from this com-
bined intervention are not usually curative. Inflammation 
proceeds different phases. The phagocytic phase involves 
removal of debris from the site of injury followed by a pro-
liferative phase characterized by revascularization aided by 
angiogenesis and extracellular matrix deposition, and finally, 
a modeling phase where wound retraction and tissue homeo-
stasis are achieved.7,8 It has been suggested that secondary 
mechanisms may exacerbate complications, and therefore, 
controlling the secondary phase is also important for mod-
ifying the deficits.9 The identification of signal molecules is 
important to develop an understanding of the repair mecha-
nisms. Current research is, therefore, focused on discovering 
newer molecular targets on which treatment modalities for 
acute SCI can be tested.
Many molecules are involved in injury mechanisms. Vas-
cular endothelial growth factor (VEGF) has been studied in 
the pathogenesis of SCI and known to have dual neurotropic 
effects: by directly acting on the neurons to promote neurite 
extension and by activating glial cells that produce various 
growth factors promoting neuronal growth,10making it an 
attractive target for investigation in SCI.11 Similarly, the heat 
shock proteins (HSPs) are primarily released because of acute 
stress, and levels of expression of these highly conserved pro-
teins are increased following SCI to preserve neuronal cells 
and repress chronic inflammation.12-14 Conversely, monocyte 
chemoattractant protein-1 (MCP-1) recruits cells to the site 
of injury that includes memory T cells, monocytes, and den-
dritic cells.15 In this respect, it is not clear whether recruited 
immune cells exacerbate tissue damage or promote repair16 
but likely depend on the type of cells involved. A delicate 
balance between the two can be deciphered by sampling 
cerebrospinal fluid (CSF) at various time intervals.17 Fur-
thermore, SCI and its long-term neurological deficits involve 
apoptosis of neurons and oligodendroglia in regions unaffect-
ed by the initial injury. This regulated apoptosis is executed 
through the caspase family of cysteine proteases.18
The aforementioned molecules are interrelated through 
various pathways and are involved in the pathogenesis of 
SCI. We, therefore, examined the role of these molecules in 
neuronal protection in acute SCI with the hope that this will 
result in the emergence of newer treatment targets for devel-
oping treatment modalities or predicting injury outcome.
Methods
Recruitment of Participants
All patients with acute traumatic SCI who presented to ATC 
emergency of the Post Graduate Institute of Medical Education 
and Research (PGIMER) trauma center in Chandigarh, India, 
between January 1, 2016, and February 26, 2017, were con-
sidered. Patients with sustained acute traumatic SCI with neu-
rological deficits within a wide age group representing injury 
from all vertebrae levels were included in the study. Patients 
with any other comorbidities, injury to other organs, and with-
out neurological deficits were excluded from the study. A total 
of 42 patients had met the inclusion criteria. All 42 patients 
were examined clinically and advised the requisite investiga-
tions with noncontrast computed tomography. The first sam-
ples for all 42 patients were taken in the emergency room and 
followed up after 30 days. Fourteen patients were lost in the 
follow-up and therefore excluded from the study. The remain-
ing 28 patients were included in the study (►Fig. 1).
Treatments Given
All patients underwent posterior decompression surgery with 
pedicle screw fixation for posterior spinal fusion. Surgery was 
done within 10 days from the date of injury. After surgery, all 
patients were additionally treated with aceclofenac 75 mg for 
2 weeks, hydrocortisone 100 mg thrice daily for 5 days, and 
antibiotics (cephalosporin and amikacin) for 5 days.
Fig. 1 The work flow of the study conducted to estimate the expres-
sion levels of different genes. ELISA, enzyme-linked immunosorbent 
assay; HSP-27, heat shock protein-27; MCP-1, monocyte chemo-
attractant protein-1; VEGFR-1, vascular endothelial growth factor 
receptor-1.
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Follow-Up Period
Each patient was followed up after 30 days, and blood sam-
ples were taken on the 1st day and 30th day. The first day 
was considered as the date of the presentation with injury in 
the hospital. At the 30th day, no neurological improvements 
were observed in any of the patients.
Ethical Committee Approval
The ethical approval for the recruitment of the participants 
and to conduct the study was taken from the Institutional 
Ethical Committee, PGIMER, Chandigarh, vide letter number 
NK/558/Res, dated February 4, 2014.
Sample Collection and Isolation of Peripheral Blood 
Monocytes, Plasma, and Serum
Five milliliters of blood was collected in a serum separator tube 
from SCI patients at day 1 (before intervention) and day 30. It 
was subjected to centrifugation for 15 minutes at 3000 rpm, and 
serum was collected. Blood was also collected in an ethylenedi-
aminetetraacetate tube and kept at room temperature for ~2 to 
3 hours to settle. The upper yellowish portion was collected and 
layered on an equal volume of Histopaque and centrifuged at 
1800 rpm for 30 minutes. Finally, from the interphase of plasma 
and Histopaque, a buffy coat of peripheral blood mononuclear 
cells (PBMCs) was collected and stored in ribonucleic acid (RNA) 
later (Sigma Aldrich, United States), while plasma was collected 
in a separate vial and stored in–80°C ultrafreezer.
Enzyme-Linked Immunosorbent Assay
Enzyme-linked immunosorbent assay (ELISA) was performed 
to determine the protein expression in serum samples at 
both time points for CASPASE-3 and HSP-27. Analysis was 
made using commercially available ELISA kits (Genxbio). 
Briefly, serum samples were plated on a precoated antibody 
ELISA plates and incubated for 2 hours at 37°C. The washing 
with buffer was followed by secondary antibody incubation 
at room temperature for 1 hour. Absorbance was taken at 450 
nm using ELISA reader as described by the manufacturer. 
Total protein concentration of samples was estimated using 
the Bradford method. A standard curve using bovine serum 
albumin was used as a protein standard, and ELISA concen-
trations were further normalized by their respective total 
protein concentrations.
RNA Isolation and cDNA Synthesis
PBMCs stored in RNA later were used for RNA isolation. Cells 
were washed using 1X PBS to remove RNA later, and then 
RNA isolation was performed using a commercially available 
kit (Qiagen, United States). RNA was used as a template to 
synthesize complementary deoxyribonucleic acid (cDNA) 
as per kit protocol (Thermo Scientific, United States). The 
expression of different genes was determined by subject-
ing cDNA to real-time polymerase chain reaction (RT-PCR) 
analysis (Applied Biosystems) using specific primers (Sigma, 
 United States and Eurofins, Genomics) (►Fig. 1).
Reverse Transcriptase Polymerase Chain Reaction
Marker gene expression was analyzed by RT-PCR. As angio-
genic, inflammatory, and stress-related markers may change 
following SCI, the mRNA expression of VEGFR-1, VEGFR-2, 
HSP-27, and MCP-1 was normalized to B-actin housekeeping 
gene and subsequently quantified. The quantitative PCR data 
were analyzed using the method of Livak and  Schmittgen19. 
The primer annealing temperature was optimized using 
 gradient PCR validated by agarose gel electrophoresis. The 
samples were subjected to PCR analysis using specific prim-
ers. The relative fold change was determined for each sample. 
The primer details are shown in ►Table 1.
Statistical analysis
All the results were expressed as mean ± standard error of 
mean. The data were statistically analyzed using SPSS ver-
sion 16.0. Data normality was analyzed using 1-KS sampling. 
The statistical significance of data was computed using the 
Mann–Whitney U test, and p < 0.05 was considered as statis-
tically significant.
Results
Our study included 17 male patients (60.7%) and 11 female 
patients (39.3%) (►Fig.  2A), suggesting higher incidence of 
SCI in male patients in accordance with the present trend.20 
Minimum age of the patient was 17 years and the maximum 
was 65 years, with the mean age being 41.07 ± 13.711 years 
(►Fig.  2B). Of 28 patients, 14 patients sustained injury to 
thoracic spine, 10 patients to lumbar spine, and 4 patients to 
cervical spine (►Fig. 2C).
Table 1  The sequence of the primers and annealing temperature used for polymerase chain reaction
Gene 
name
Forward primer sequence Reverse primer sequence Annealing 
temperature
VEGFR-1 GCTGTGCGCGCTGCTT AACTCAGTTCAGGACCTTTTAATTTTGA 63°C
VEGFR-2 TGATACTGGAGCCTACAAGTGCTT CCTGTAATCTTGAACGTAGACATAAATGA 58.9°C
HSP-27 CGTGGTGGAGATCACTGGCAAGC CGGGCCTCGAAAGTGACCGG 63°C
MCP-1 5′-AGCAGCAAGTGTCCCAAAGA-3′ 5′-TTGGGTTTGCTTGTCCAGGT-3′ 64.2°C
Abbreviations: HSP-27, heat shock protein-27; MCP-1, monocyte chemoattractant protein-1; VEGFR-1, vascular endothelial growth factor 
receptor-1. 
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Protein Estimation
ELISA was performed to estimate change in protein levels of 
HSP-27 and CASPASE-3 after 1 month of follow-up. Protein 
estimation using ELISA showed no significant difference in 
the level of HSP-27 (p = 0.423) and CASPASE-3 (p = 0.979) 
between day 1 and day 30 (►Fig. 3). We further analyzed the 
data and found that there was no significant change in both 
CASPASE-3 and HSP-27 in relation to age, gender, severity, 
and level of vertebrae involved (data not shown).
Gene Expression
VEGFR-2 expression was found to be elevated after 30 days 
of post-trauma to spinal cord; however, the increase was 
not statistically significant (p = 0.867). Similarly, expression 
of VEGFR-1 showed no significant change in the follow-up 
group (►Figs.  4A,  B). The relative expression of HSP-27 on 
day 1 was compared with day 30 (►Fig. 5), and we found a 
significant decrease in the expression of HSP-27 (p = 0.001) at 
30th day posttrauma. Expression of MCP-1 showed a signifi-
cant elevation at 30th day posttrauma (►Fig. 6).
Discussion
SCI is a devastating condition with serious consequenc-
es. Proinflammatory and anti-inflammatory mechanisms 
participating in the secondary phase play a decisive role 
Fig. 2 (A) Pie chart showing gender distribution in the study. (B) Histo-
gram showing age distribution. (C) Bar chart showing percentage-wise 
distribution of levels of vertebral injury.
Fig. 3 Comparing (A) CASPASE-3 and (B) heat shock protein-27 expression in serum at day 0 and day 30 post–spinal cord injury. HSP-27, heat 
shock protein-27.
Fig. 4 Fold change in gene expression levels of vascular endothelial growth factor receptor-1 (A) and vascular endothelial growth factor recep-
tor-2 (B) at day 0 and day 30 post–spinal cord injury.
Fig. 5 Fold change in gene expression levels of heat shock protein-27 
at day 0 and day 30 post–spinal cord injury. *p > 0.05.
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in the outcome.21 Different biomarker genes are expressed 
in a complex manner during secondary phase, but only 
a few of them are analyzed. The protective mechanisms 
include upregulation of regeneration-associated genes and 
neurotrophic factors.22 The present study was performed 
to probe any possible pattern in the expression of various 
angiogenetic biomarkers such as VEGFR-1, VEGFR-2, HSP-
27, MCP-1, and CASPASE-3 in traumatic SCI so that the 
understanding of aforementioned secondary mechanisms 
could serve as a basis for devising new strategies for phar-
macological interventions. Because of limited funds, ELISA 
could be performed only for CASPASE-3 and HSP-27.
VEGF promotes cell survival by reducing apoptosis 
and repairing blood vessel damage.23 Quantification of 
CASPASE-3 protein by ELISA post-SCI did not show any 
significant change in the posttraumatic period, which may 
suggest that CASPASE-3 is not altered by VEGFR, suggest-
ing its redundant role in angiogenesis and neurogenesis 
post-SCI. These studies are in contrast to those performed 
by Voss et al,24 where VEGF has shown to have a nonredun-
dant role. As discussed earlier, VEGF helps in restoration 
of blood vessels’ damage by promoting angiogenesis and 
thereby inhibits the apoptotic machinery. VEGF exerts its 
angiogenic effects through its two major tyrosine kinas-
es receptors, VEGFR-1 and VEGFR-2. Whereas VEGFR-1 
recruits hematopoietic precursor cells and helps in the 
migration of monocytes and macrophages, VEGFR-2 plays 
a major role in the regulation of vascular endothelial cells.25 
Quam et al26 reported the stimulation of VEGFR following 
ischemia resulting in the formation of newer vasculature 
and it has positive effects in promoting neurogenesis. Fol-
lowing neurological stress or trauma or any kind of injury, 
VEGFR is shown to be released by microglial, astrocytes, 
and monocytes as a compensatory response for inflamma-
tory reactions and to protect neurons. Our study analyzed 
the PBMCs for any possible change in the expressions of 
both VEGFR-1 and VEGFR-2. As reported, the increase in 
expressions of both VEGFR-1 and VEGF-2, even though not 
significant, may exert neuronal protection and regenera-
tion by promoting effects through angiogenesis. Interest-
ingly, their increase can be antagonized by the inflamma-
tory mechanisms following posttrauma, thus indicating 
the fine molecular balance that directs the cellular homeo-
stasis. Insignificant change in the VEGF-1 and -2 can be 
due to delayed recovery, which can be investigated further 
with a long-term follow-up with sampling at intermittent 
intervals. Furthermore, antagonistic mechanisms to neu-
ronal recovery like deposition of chondroitin sulfate at 
neuronal ends that occur in secondary phase after spine 
trauma can be contributory.27 A study done in rats found 
that the expression of VEGFR mRNA and protein levels 
get upregulated immediately following SCI; however, the 
levels get normalized after 14 days of SCI.28 Another study 
reported a significant decrease in VEGF levels after 1 day 
of surgery and it was maintained after 1 month post-SCI.29 
HSP-27, being a stress protein and released from living 
cells on exposure to stress that occurs usually in chronic 
diseases, trauma, and infections, has been reported to be 
elevated after SCI and suggesting that it plays a key role in 
modulating secondary phase of spine injury by acting as a 
molecular chaperone and repairing the partially damaged 
neurons.14 Consistent with this study, a pre- and posttreat-
ment study on rats with peroxisome proliferator-activat-
ed receptor inhibitors showed the protective neurologi-
cal response that is due to elevation of HSP.30,31 There are 
additional studies with HSP-27 that shows its angiogenic 
and neurogenic potential. A few studies have also shown 
that the elevation of this protein following any kind of 
stress or tissue injury is associated with angiogenesis.32 In 
contrast to this, mutations in HSP 27 result in decreased 
expression of HSP and binding of heat shock factor to heat 
shock element resulting in impaired neuroprotection.33,34 
We did not analyze any single nucleotide polymorphisms 
(SNPs) in HSP-27. In this context, a significant decrease in 
the levels of HSP-27 in the posttraumatic period indicates 
a subdued compensatory response. The cause of delayed 
activation could not be analyzed although HSP-27 and 
CASPASE-3 expression are often with apoptotic and angio-
genic activity.
Similarly, the expression of MCP-1 in the acute phase of 
posttraumatic SCI was elevated within 30 days from the time 
of injury. This can be an intrinsic response to the inflam-
mation caused after secondary SCI since MCP1 is released 
by monocytes, macrophages and dendritic cells in response 
to inflammatory reaction. A study in a rat model report-
ed increased expression of MCP-1 in secondary SCI, due to 
inflammatory cytokines—interleukin-1β and tumor necrosis 
factor α. The same study reported that after anti-MCP-1 gene 
therapy, levels of MCP-1 expression, monocytes, and macro-
phage infiltration were reduced, further supporting inflam-
matory role of MCP-1. The reduction of MCP-1 expression is, 
therefore, protective during secondary SCI as it inhibits apop-
totic process and reduces neuronal and astrocyte injury.35
It has been reported that the angiogenic role of MCP-1 
through the p44/42 MAPK (Erk1/2) pathway upregulates 
hypoxia-inducible factor (e.g., VEGF) in the aortic endothe-
lial cells.36 Upregulating the levels of VEGF-A also results in 
angiogenesis, pointing out a possible compensatory role by 
VEGF in SCI.37 It is possible that after SCI, there is activation of 
chemotactic activity resulting in an increase in the number 
Fig. 6 Fold change in gene expression levels of monocyte chemoat-
tractant protein-1 at day 0 and day 30 post–spinal cord injury. *p > 0.05
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of various chemotactic factors such as MCP-1, which further 
activates VEGFR (►Fig.  7). We postulate that VEGFR-1 and 
VEGFR-2 and MCP-1 are important biomarkers released after 
SCI trauma and this is supported by other studies.31,38 They 
may exert their angiogenic influence to protect neurons from 
senescence and activate neuronal regeneration; however, 
their interaction with HSP-27 at other time points remains 
to be determined.
Limitations
The study consisted of a small sample size, and study par-
ticipants were not studied with long-term follow-up. This 
study did not consider patients with any other comorbid con-
ditions. The study was only limited to the group of patients 
who had undergone decompression surgery
Conclusion
The decreased mRNA HSP-27 expression may indicate a sub-
dued compensatory response or delayed activation, which 
needs further investigation at other time points. On the 
other hand, increased MCP-1 expression can constitute an 
intrinsic response to the inflammation caused after second-
ary SCI, suggesting a possible inverse association of HSP-27 
and MCP-1 with SCI. These may be investigated as potential 
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